Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type I-associated myelopathy

Internal Medicine

Volumn 38, Issue 9, 1999, Pages 717-721

  Fujimoto, Takeshi ^a   Nakamura, Tatsufumi ^a,b   Furuya, Takafumi ^a   Nakane, Shunya ^a   Shirabe, Susumu ^a   Kambara, Chiaki ^a   Hamasaki, Shinji ^a   Yoshimura, Toshiro ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Human T lymphotropic virus type I (HTLV I) associated myelopathy (HAM); Interleukin (IL) 4,IL 10; Pentoxifylline (PTX)

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; FEMALE; HELPER CELL; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; SPASTICITY; SPINAL CORD DISEASE;

EID: 0032861908     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.717     Document Type: Article

References (21)

1. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet i: 1031-1032, 1986.
2. Osame M, Matsumoto M, Usuku K et al. Chronic progressive myelopahty associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia like cells. Ann Neurol 21: 117-122, 1987.
3. Shibayama K, Nakamura T, Nagasato K, Shirabe S, Tsujihata M, Nagataki S. Interferon-alpha treatment in HTLV-I-associated myelopathy, studies of clinical and immunological aspects. J Neurol Sci 106: 186-192, 1991.
4. Matsuo H, Nakamura T, Tsujihata M, et al. Plasmapheresis in treament of human T-lymphotropic virus type-I-associated myelopahty. Lancet ii: 1109-1113, 1988.
5. Shirabe S, Nakamura T, Tsujino A, et al. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 151: 97-101, 1997.
6. Tsujino A, Nakamura T, Nishiura Y, et al. Pentoxifylline down-regulates adhesion molecule expression and inflammatory cytokine production in cultured peripheral blood mononuclear cells from patients with HTLV-I-associated myelopathy. J Neuroimmunol 73: 191-196, 1997.
7. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989.
8. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 12: 227-257, 1994.
9. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeriainduced macrophages. Science 260: 547-549, 1993.
10. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-gamma anf IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 156: 1442-1447, 1996.
11. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12: 635-673, 1994.
12. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammtory autoimmune disease. J Exp Med 180: 1961-1966, 1994.
13. Trembleau S, Penna G, Bosi E, et al. Interleukin-12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181: 817-821, 1995.
14. Donckier V, Abramowicz D, Bruyns C, et al. IFN-γ prevents Th2 cell-mediated pathology after neonatal injection of semiallogenic spleen cells in mice. J Immunol 153: 2361-2368, 1994.
15. Nishiura Y, Nakamura T, Ichinose K, et al. Increased production of inflammtory cytokines in cultured CD4+ cells from patients with HTLV-I-associated myelopathy. Tohoku J Exp Med 179: 227-233, 1996.
16. Furuya T, Nakamura T, Fujimoto T, et al. Elevated levels of interleukin-12 and interferon-garnma in patients with human T lymphotrophic virus type I-associated myelopathy. J Neuroimmunol 95: 185-189, 1999.
17. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 28: 50-56, 1990.
18. Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drug 34: 50-97, 1987.
19. Van der Pouw Kraan TCTM, Boeiji LCM, Smeenk RJT, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181: 775-779, 1995.
20. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146: 108-113, 1991.
21. Rieckmann P, Weber F, Güther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64: 193-200, 1996.